eligibility_summary
Eligible: confirmed advanced/metastatic nectin‑4–expressing solid tumor after ≥1 prior therapy or no standard options. Exclude: active/uncontrolled CNS mets, other malignancies, cardiovascular events in past 6 mo, ≥Grade 2 neuropathy, HbA1c ≥8% or uncontrolled diabetes/diabetic neuropathy, active ocular disease, severe liver disease/cirrhosis, ILD/pneumonitis within 6 mo, other major comorbidities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06265727 tests: 1) CRB-701, a nectin‑4–targeted antibody–drug conjugate (ADC), as monotherapy and 2) CRB-701 combined with an anti–PD‑1 monoclonal antibody checkpoint inhibitor (listed as spartalizumab). Mechanisms: CRB-701’s antibody binds nectin‑4 on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor cell death, the anti–PD‑1 antibody blocks PD‑1 to restore and enhance T‑cell–mediated antitumor immunity. Targets: nectin‑4–expressing solid tumor cells (cell adhesion molecule on tumor cell membranes) and the PD‑1/PD‑L1 immune checkpoint pathway on T lymphocytes within the tumor microenvironment.